Scholarlink

<p>Cytomegalovirus (CMV) reactivation remains a major complication after hematopoietic cell transplantation (HCT), particularly in high-risk settings. Although the antigenemia (AG) assay has long been the standard CMV monitoring tool in Japan, quantitative PCR (qPCR) offers improved sensitivity and is now widely adopted. We analyzed a total of 1878 samples from 231 HCT recipients who underwent CMV monitoring at multiple centers. We evaluated the correlation between AG and qPCR results, determined qPCR thresholds equivalent to AG positivity, and compared actual AG-guided therapy durations with simulated qPCR-guided therapy. Among 1878 sample sets, AG and qPCR showed strong correlation (r = 0.65) and high concordance (87.6%). Median qPCR values increased with AG positivity level. ROC analysis identified qPCR cut-offs corresponding to 2 and 10 AG-positive cells as 99.5 and 815&#xa0;IU/mL, respectively. Of 57 qPCR-only episodes, 32 resolved without AG conversion; higher qPCR levels were associated with treatment need. Simulated qPCR-guided therapy durations closely matched AG-guided therapy (median 4&#xa0;weeks), but some cases required longer treatment. qPCR-based CMV monitoring is concordant with AG and feasible for preemptive therapy. Careful interpretation of low-level viremia is warranted to avoid overtreatment. Further data are needed to refine qPCR thresholds in transplant settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients

  • 期刊论文

  • 发表日期：

    2025年12月1日

查看全文
  • Yasuo Mori,
  • Kentaro Kohno,
  • Toshiyuki Ueno,
  • Jun Odawara,
  • Noriaki Kawano,
  • Koji Nagafuji,
  • Takuya Harada,
  • Goichi Yoshimoto,
  • Takuro Kuriyama,
  • Shingo Urata,
  • Kazushi Tanimoto,
  • Yoshikane Kikushige,
  • Ryosuke Ogawa,
  • Yuju Ohno,
  • Tomohiko Kamimura,
  • Yoshikiyo Ito,
  • Ken Takase,
  • Tetsuya Eto,
  • Tomoaki Fujisaki,
  • Kazuki Tanimoto,
  • Yuta Katayama,
  • Koichi Akashi,
  • Katsuto Takenaka,
  • Toshihiro Miyamoto

摘要

Cytomegalovirus (CMV) reactivation remains a major complication after hematopoietic cell transplantation (HCT), particularly in high-risk settings. Although the antigenemia (AG) assay has long been the standard CMV monitoring tool in Japan, quantitative PCR (qPCR) offers improved sensitivity and is now widely adopted. We analyzed a total of 1878 samples from 231 HCT recipients who underwent CMV monitoring at multiple centers. We evaluated the correlation between AG and qPCR results, determined qPCR thresholds equivalent to AG positivity, and compared actual AG-guided therapy durations with simulated qPCR-guided therapy. Among 1878 sample sets, AG and qPCR showed strong correlation (r = 0.65) and high concordance (87.6%). Median qPCR values increased with AG positivity level. ROC analysis identified qPCR cut-offs corresponding to 2 and 10 AG-positive cells as 99.5 and 815 IU/mL, respectively. Of 57 qPCR-only episodes, 32 resolved without AG conversion; higher qPCR levels were associated with treatment need. Simulated qPCR-guided therapy durations closely matched AG-guided therapy (median 4 weeks), but some cases required longer treatment. qPCR-based CMV monitoring is concordant with AG and feasible for preemptive therapy. Careful interpretation of low-level viremia is warranted to avoid overtreatment. Further data are needed to refine qPCR thresholds in transplant settings.